On May 25, 2026, Eternal Medicines officially announced that the Korean Ministry of Food and Drug Safety (MFDS) has approved the new drug application for eltromod (trade name: Vistip®) . This drug will be used to treat adult patients with moderate to severe active ulcerative colitis who have not responded well to or are intolerant of traditional treatments or biologics, bringing a new treatment option to patients in Korea.

Ulcerative colitis, a chronic inflammatory bowel disease, has an incompletely understood etiology and is characterized by a high recurrence rate. Typical symptoms such as mucus and bloody stools, abdominal pain, and diarrhea severely impact patients' quality of life. In recent years, the incidence of this disease has been steadily increasing in Asia, creating an urgent clinical need for safe, effective, and convenient treatment drugs.

Visip® is a highly selective sphingosine-1-phosphate (S1P) receptor modulator taken orally once daily. Through optimized pharmacological design, it precisely targets S1P receptors 1, 4, and 5, improving the convenience of medication while ensuring therapeutic efficacy, making it more suitable for long-term chronic disease management scenarios.

To date, eltromod has been approved for marketing in multiple countries and regions around the world, covering major pharmaceutical markets such as the United States, the European Union, Japan, mainland China, and South Korea. This approval in South Korea further enhances its global presence, enabling it to continue providing standardized, high-quality oral treatment options for patients with moderate to severe ulcerative colitis worldwide.

https://bydrug.pharmcube.com/news/detail/b2fae0a1bc690b05dd5c8785bd2cf4f4